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LETTERS TO THE EDITOR
A Novel Germline Mutation in the hMLH1 DNA Mismatch
Repair Gene in a Patient with an Isolated Cystic Sebaceous
Tumor
To the Editor:
A germline mutation in one of at least five DNA mismatch repair
(MMR) genes (Kolodner et al, 1994; Miyaki et al, 1997; Peltoma¨ki
and Vasen, 1997) leads to a significantly increased risk for autosomal
dominant inherited neoplasia: different types of internal cancer
(Lynch syndrome, hereditary non-polyposis colorectal cancer,
HNPCC) and, in some families, additional sebaceous skin tumors
(Muir–Torre syndrome, MTS). In MTS the sebaceous lesions
comprise sebaceous adenomas, epitheliomas, or rarely carcinomas
(Lynch et al, 1985; Schwartz and Torre, 1995; Esche et al, 1997).
A considerable proportion of MTS patients with an MMR defect
exhibits an HNPCC-typical genomic instability (microsatellite
instability) in both the internal tumors and the sebaceous skin
tumors (Honchel et al, 1994; Kruse et al, 1996; Esche et al, 1997).
In contrast, the frequency of microsatellite instability in a series of
randomly selected skin tumors was shown to be less than 5%
(Quinn et al, 1995). So far, patients with DNA mismatch repair
defects are ascertained through strict clinical criteria for HNPCC
or MTS. It is not known whether distinct histopathologic features
of isolated sebaceous skin tumors alone justify the initiation of a
molecular genetic analysis for an MMR defect.
In a previous study on the Muir–Torre phenotype, we found a
high frequency of DNA MMR germline mutations in 16 patients
of the MTS subpopulation with colorectal cancer (Kruse et al,
1998). The histopathologic re-examination of the sebaceous skin
tumors in this sample revealed – besides a broad spectrum of well-
known sebaceous neoplasms – a disproportionate number of
sebaceous tumors with a distinctive cystic morphology; these
distinctive tumors occured in five of the 16 patients. Cystic
sebaceous tumors are well circumscribed, large, and deeply located
dermal sebaceous proliferations with a cystic growth pattern. They
represent a morphologic spectrum ranging from benign cystic
sebaceous adenomas to more proliferating cystic sebaceous tumors
in which it is impossible by morphology alone to exclude an
evolving cystic sebaceous carcinoma with certainty. Cystic sebaceous
tumors differ from common sebaceous adenomas, epitheliomas, or
carcinomas and have so far only been described in MTS patients
(Steffen and Ackerman, 1992; Nussen and Ackerman, 1998). Thus,
these tumors are probably a specific cutaneous marker for an
inherited DNA MMR defect.
This hypothesis prompted us to perform a molecular genetic
study in a male individual, ascertained solely through an isolated
sebaceous skin tumor with a characteristic cystic growth pattern
that developed at the age of 54 y. The large well-circumscribed
neoplasm fills the whole dermis and reaches at the base the upper
subcutis (Fig 1a). It belongs to the more proliferating variants of
cystic sebaceous tumors. The tumor reveals a more lobulated
growth pattern with a folded cyst wall. Analogous to normal
sebaceous glands, the cyst wall shows a small peripheral rim of bluish-
appearing basaloid cells representing nonvacuolated sebocytes. More
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Figure 1. Proliferating cystic sebaceous tumor from the examined
patient (hematoxylin and eosin stain). (a) Scanning magnification
(310; scale bar, 0.8 mm). (b) High power (3100; scale bar, 0.08 mm):
periphery of the cystic sebaceous tumor shows fully vacuolated sebaceous
cells with disintegration of sebocytes to central masses of sebum.
Figure 2. Germline mutation in the hMLH1 gene in the patient
(Exon 2: 150insT). The figure shows the sequence section of the coding
strands (mutation in second line, see arrow) as obtained by semiautomated
analysis. The mutation was confirmed by sequence analysis of the
opposite strand.
centrally confluent masses of vacuolated sebaceous cells surround
large areas of sebum (Fig 1b). Sebum and cornified cells as remnants
of sebaceous ductal differentiation fill the central cavity of the
tumor. The patient had no history of any internal malignancy. He
reported that his father had died from gastric cancer at the age of 36.
DNA extracted from paraffin-embedded tissue sections of the
cystic sebaceous tumor (using the QIAamp tissue kit; Qiagen, Hilden,
Germany) revealed high genomic instability typical of HNPCC
tumors: eight of the 10 microsatellite markers tested showed addi-
tional alleles in tumor DNA compared with normal DNA. The
search for germline mutations in this patient by protein truncation test
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followed by semiautomated sequencing (using an ABI 377 sequencer;
Applied Biosystems, Weiterstadt, Germany), uncovered a novel
frameshift mutation in exon 2 of the DNA MMR gene hMLH1
(150insT; Fig 2). This mutation is predicted to lead to a premature
stop codon that results in a truncated, nonfunctional DNA repair
protein. In patients with MTS, only two different mutations in the
hMLH1 gene have been reported so far, whereas 12 mutations have
been identified in the hMSH2 gene (Kolodner et al, 1994; Liu et al,
1994; Kruse et al, 1996, 1998; Bapat et al, 1996).
In summary, a patient with an inherited DNA MMR defect
(HNPCC) was identified for the first time on the basis of a single
distinctive cutaneous tumor. Schwartz and Torre (1995) already
pointed out that there may be a hiatus of many years before both
elements – the sebaceous neoplasm and the internal cancer – are
present in a patient to allow the diagnosis of MTS. Our results
indicate that patients with isolated cystic sebaceous tumors are very
likely to have an inherited DNA MMR defect. For these patients
a lifelong surveillance for skin tumors and internal cancer of the
HNPCC spectrum should be recommended.
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Superantigens in T Cell Mediated Skin Diseases – More than a
Coincidence!
To the Editor
We read with interest the article by Jappe et al in the May 1998
issue of this journal, analyzing the frequency of superantigen-
producing Staphylococcus aureus isolates in patients suffering from
atopic dermatitis and nonatopic, healthy controls. The authors
found that 45% of strains from atopic dermatitis patients (n 5 22)
were capable of producing superantigens that did not exceed the
number of S. aureus strains isolated from healthy carriers capable
of superantigen production (n 5 8). Based on these findings,
the authors question the hypothesis that skin colonization with
superantigen-producing S. aureus is an essential prerequisite in the
pathogenesis of atopic dermatitis (Jappe et al, 1998).
We believe, however, that the design of the study is not suitable
to address this question. The authors analyzed the effect of a
defined environmental factor (staphylococcal superantigens) on two
different groups of individuals: one with a disease-prone genetic
background (i.e., atopy), the other one without this genetic
background. The fact that an environmental factor is not sufficient
to induce a disease in the absence of a disease-prone genetic
background, does not exclude its importance in the disease process.
Gliadin, for example, is tolerated by the large majority of individuals.
Nevertheless, in the presence of a defined genetic background, i.e.,
specific HLA class II DQ and DR alleles, gliadin causes celiac
disease (Howell et al, 1986; Lundin et al, 1994). If Jappe et al
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applied the same criteria to draw conclusions in the study of the
pathogenecity of gliadin, they would conclude that gliadin is not
an essential prerequisite in the pathogenesis of celiac disease.
This clearly emphasizes that besides defined (as in celiac disease)
or multifactorial (as in atopy) environmental triggers, the genetic
background is of major importance. With respect to psoriasis and
superantigens we recently demonstrated that superantigens do only
induce a psoriasiform dermatitis if the genetic background of psoriasis
is given, but not in healthy individuals (Boehncke et al, 1996). Addi-
tionally, in patients with the genetic background of atopy or psoriasis
we found that patients colonized with superantigen-producing S.
aureus strains suffer from a more severe disease compared with patients
that are colonized by S. aureus strains not capable of superantigen
production (Zollner et al, manuscript submitted).1
With respect to the study by Jappe et al, we think the authors
can only conclude that in the absence of the atopic background
bacterial superantigens are not sufficient to induce (atopic) derma-
titis. No conclusion should be drawn on the relevance of super-
antigens in atopic dermatitis.
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